EC Number |
Recommended Name |
Source Tissue |
Reference |
---|
1.1.1.14 | L-iditol 2-dehydrogenase |
hippocampus |
- |
712376 |
1.1.1.146 | 11beta-hydroxysteroid dehydrogenase |
hippocampus |
- |
654196, 741117 |
1.1.1.146 | 11beta-hydroxysteroid dehydrogenase |
hippocampus |
of animals that received betamethasone as a fetus, or whose mothers received betamethasone during pregnancy. Adult animals demonstrate increased mineralocorticoid and 11beta-HSD2 mRNA levels |
688010 |
1.1.1.149 | 20alpha-hydroxysteroid dehydrogenase |
hippocampus |
- |
763094 |
1.1.1.178 | 3-hydroxy-2-methylbutyryl-CoA dehydrogenase |
hippocampus |
- |
673530 |
1.1.1.315 | 11-cis-retinol dehydrogenase |
hippocampus |
7% mRNA expression of Rdh5 compared to liver |
690797 |
1.1.1.357 | 3alpha-hydroxysteroid 3-dehydrogenase |
hippocampus |
- |
763094 |
1.1.1.51 | 3(or 17)beta-hydroxysteroid dehydrogenase |
hippocampus |
the relative expression level of 17beta- or 3beta-hydroxysteroid dehydrogenase is approximately 1.3-1.5fold higher at the neonatal than at the adult stage |
696052 |
1.1.1.62 | 17beta-estradiol 17-dehydrogenase |
hippocampus |
no sex differences in enzyme expression |
740245 |
1.1.1.95 | phosphoglycerate dehydrogenase |
hippocampus |
- |
700437 |
1.1.1.B40 | 11beta-hydroxysteroid dehydrogenase (NAD+) |
hippocampus |
- |
654196, 743428 |
1.1.1.B40 | 11beta-hydroxysteroid dehydrogenase (NAD+) |
hippocampus |
of animals that received betamethasone as a fetus, or whose mothers received betamethasone during pregnancy. Adult animals demonstrate increased mineralocorticoid and 11beta-HSD2 mRNA levels |
688010 |
1.10.5.1 | ribosyldihydronicotinamide dehydrogenase (quinone) |
hippocampus |
- |
712829 |
1.11.1.6 | catalase |
hippocampus |
catalase activity is decreased dramatically after forebrain ischemia insult, no significant difference in catalase activity between control group and sham-operated group and curcumin-treted group |
676165 |
1.11.1.9 | glutathione peroxidase |
hippocampus |
- |
677215, 685439, 686868, 695604 |
1.11.2.2 | myeloperoxidase |
hippocampus |
- |
700150 |
1.13.11.27 | 4-hydroxyphenylpyruvate dioxygenase |
hippocampus |
abundantly expressed in neurons of |
658410 |
1.13.11.31 | arachidonate 12-lipoxygenase |
hippocampus |
- |
659765, 705902 |
1.13.11.34 | arachidonate 5-lipoxygenase |
hippocampus |
high level of expression, colocalization of 5-lipoxygenase and 5-lipoxygenase-activating protein in CA1 pyramidal neurons |
439477 |
1.13.11.34 | arachidonate 5-lipoxygenase |
hippocampus |
increased enzyme content in older rats, overview |
-, 689167 |
1.13.11.5 | homogentisate 1,2-dioxygenase |
hippocampus |
- |
743037 |
1.13.11.52 | indoleamine 2,3-dioxygenase |
hippocampus |
- |
700466, 712821, 713002, 726330 |
1.13.11.52 | indoleamine 2,3-dioxygenase |
hippocampus |
expression of TDO mRNA is significantly increased in the hippocampus of Alzheimer's disease patient brain. TDO co-localizes with quinolinic acid, neurofibrillary tangles-tau and amyloid deposits in the hippocampus of Alzheimer's disease patient brain |
726330 |
1.13.11.52 | indoleamine 2,3-dioxygenase |
hippocampus |
neurons, level of activity is lower than in monocytic cells in lymph nodes |
666461 |
1.13.11.52 | indoleamine 2,3-dioxygenase |
hippocampus |
the enzyme is upregulated by interferon-gamma in neurons of the hippocampus |
666461 |
1.13.11.6 | 3-hydroxyanthranilate 3,4-dioxygenase |
hippocampus |
- |
-, 675782 |
1.14.11.67 | [histone H3]-trimethyl-L-lysine4 demethylase |
hippocampus |
- |
-, 713122 |
1.14.13.39 | nitric-oxide synthase (NADPH) |
hippocampus |
- |
440224, 686293 |
1.14.14.19 | steroid 17alpha-monooxygenase |
hippocampus |
- |
715984 |
1.14.14.25 | cholesterol 24-hydroxylase |
hippocampus |
- |
676852, 688555, 705612, 706536, 728617 |
1.14.14.25 | cholesterol 24-hydroxylase |
hippocampus |
after kainate lesions |
675535 |
1.14.14.25 | cholesterol 24-hydroxylase |
hippocampus |
high levels |
701715 |
1.14.14.25 | cholesterol 24-hydroxylase |
hippocampus |
pyramidal neurons |
687987 |
1.14.15.15 | cholestanetriol 26-monooxygenase |
hippocampus |
- |
705935 |
1.14.15.4 | steroid 11beta-monooxygenase |
hippocampus |
- |
688009 |
1.14.15.4 | steroid 11beta-monooxygenase |
hippocampus |
primary culture of hippocampal neurons isolated from fetus |
659746 |
1.14.16.4 | tryptophan 5-monooxygenase |
hippocampus |
expression of the native truncated mutant TPH2 |
689089 |
1.14.17.3 | peptidylglycine monooxygenase |
hippocampus |
- |
728178 |
1.14.17.3 | peptidylglycine monooxygenase |
hippocampus |
PAM-1 and PAM-2 |
438587 |
1.14.99.1 | prostaglandin-endoperoxide synthase |
hippocampus |
- |
673515, 686417 |
1.14.99.1 | prostaglandin-endoperoxide synthase |
hippocampus |
PGHS-2 has highest abundance in hippocampus and cerebral cortex |
698086 |
1.14.99.1 | prostaglandin-endoperoxide synthase |
hippocampus |
PGSHS-1 has highest abundance in hippocampus and cerebral cortex |
698086 |
1.16.1.10 | ferric-chelate reductase [NAD(P)H] |
hippocampus |
native FRRS1L in hippocampus is localized at dynein, but not kinesin5B, vesicles |
-, 744983 |
1.16.3.1 | ferroxidase |
hippocampus |
- |
689209 |
1.2.1.105 | 2-oxoglutarate dehydrogenase system |
hippocampus |
- |
700476 |
1.2.1.12 | glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) |
hippocampus |
- |
743688 |
1.2.1.24 | succinate-semialdehyde dehydrogenase (NAD+) |
hippocampus |
- |
694354 |
1.2.1.25 | branched-chain alpha-keto acid dehydrogenase system |
hippocampus |
- |
763513 |
1.2.1.3 | aldehyde dehydrogenase (NAD+) |
hippocampus |
- |
693766 |
1.2.1.36 | retinal dehydrogenase |
hippocampus |
- |
725461 |
1.2.4.2 | oxoglutarate dehydrogenase (succinyl-transferring) |
hippocampus |
- |
699606 |
1.2.4.4 | 3-methyl-2-oxobutanoate dehydrogenase (2-methylpropanoyl-transferring) |
hippocampus |
- |
725082 |
1.21.99.3 | thyroxine 5-deiodinase |
hippocampus |
isozyme type III |
644804 |
1.3.1.22 | 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) |
hippocampus |
- |
710797 |
1.3.1.24 | biliverdin reductase |
hippocampus |
- |
711794, 724423 |
1.3.5.1 | succinate dehydrogenase |
hippocampus |
- |
686054 |
1.3.5.1 | succinate dehydrogenase |
hippocampus |
15-20% inhibition of complex II activity in striatum and hippocampus by methylmalonic acid at low concentrations of sucinate in the medium, but not in the peripheral tissue. the inhibitory property only occurs after exposing brain homogenates for at least 10 min with the acid, suggesting that this inhibition is mediated by indirect mechanisms |
674053 |
1.3.5.2 | dihydroorotate dehydrogenase (quinone) |
hippocampus |
high enzyme level |
713150 |
1.3.5.2 | dihydroorotate dehydrogenase (quinone) |
hippocampus |
high level both of expression and activity |
713150 |
1.4.1.27 | glycine cleavage system |
hippocampus |
in rat brain, the P-protein is confined to astrocytes. The intensity of astrocyte staining varies with regions, with the strongest staining in the hippocampus, the cerebellar cortex, the Bergmann glia in the cerebellum and the Muller cells in the retina |
758982 |
1.4.1.3 | glutamate dehydrogenase [NAD(P)+] |
hippocampus |
- |
-, 712827 |
1.4.3.1 | D-aspartate oxidase |
hippocampus |
- |
711719, 742426, 743350 |
1.4.3.13 | protein-lysine 6-oxidase |
hippocampus |
pyramidal cells: LOXL, not LOX |
659751 |
1.4.3.3 | D-amino-acid oxidase |
hippocampus |
- |
679652, 688608, 699164, 699646, 723921 |
1.4.3.5 | pyridoxal 5'-phosphate synthase |
hippocampus |
12.3% of the activity in liver |
655483 |
1.4.3.5 | pyridoxal 5'-phosphate synthase |
hippocampus |
PNPO immunoreactivities are significantly increased in the rat hippocampus accompanied by reductions in paired-pulse inhibition at 1 day and 1 week after status epilepticus |
705930 |
1.6.3.1 | NAD(P)H oxidase (H2O2-forming) |
hippocampus |
- |
712826 |
1.6.3.1 | NAD(P)H oxidase (H2O2-forming) |
hippocampus |
neuron-enriched hippocampal culture |
688550 |
1.6.99.1 | NADPH dehydrogenase |
hippocampus |
- |
673464 |
1.6.99.1 | NADPH dehydrogenase |
hippocampus |
hippocampal neuron, experimental epilepsy induced in rats by infusion of kainic acid into the lateral cerebral ventricles decreases the number of NADPH-diaphorase-positive neurons in the hippocampal formation by 55-79% |
672861 |
1.8.3.2 | thiol oxidase |
hippocampus |
- |
659578 |
1.8.3.2 | thiol oxidase |
hippocampus |
during late embryogenesis |
669636 |
1.8.4.11 | peptide-methionine (S)-S-oxide reductase |
hippocampus |
high MsrA expression level |
668581 |
1.8.5.1 | glutathione dehydrogenase (ascorbate) |
hippocampus |
- |
394027 |
2.1.1.2 | guanidinoacetate N-methyltransferase |
hippocampus |
- |
687352 |
2.1.1.348 | mRNA m6A methyltransferase |
hippocampus |
the abundance of METTL3 in wild-type mouse hippocampus is positively correlated with learning efficacy, and overexpression of METTL3 significantly enhances long-term memory consolidation |
756408 |
2.1.1.355 | [histone H3]-lysine9 N-trimethyltransferase |
hippocampus |
- |
720297 |
2.1.1.37 | DNA (cytosine-5-)-methyltransferase |
hippocampus |
different levels of global methylation in the adult rat dentate gyrus and CA1 region in comparison with the CA2 and CA3 regions. mRNA levels of DNA methyltransferases exhibit similar regional specificity and are correlated with global DNA methylation levels |
705915 |
2.2.1.1 | transketolase |
hippocampus |
thiamine-deficient diet reduces transketolase activity in both cortex and hippocampus, without significantly affecting the activities of pyruvate dehydrogenase, alpha-ketoglutamate dehydrogenase, and glucose 6-phosphate dehydrogenase |
699663 |
2.3.1.108 | alpha-tubulin N-acetyltransferase |
hippocampus |
- |
736795 |
2.3.1.21 | carnitine O-palmitoyltransferase |
hippocampus |
expression of isoforms CPT1a and CPT2 increases during brain development and is enriched in hippocampus relative to the cortex, midbrain, and cerebellum |
757462 |
2.3.1.21 | carnitine O-palmitoyltransferase |
hippocampus |
no age differences are detected in CPT2 mRNA expression in hippocampus |
757462 |
2.3.1.225 | protein S-acyltransferase |
hippocampus |
expression in the hippocampal subfield CA3 and the dentate gyrus |
709096 |
2.3.1.23 | 1-acylglycerophosphocholine O-acyltransferase |
hippocampus |
- |
755989 |
2.3.1.255 | N-terminal amino-acid Nalpha-acetyltransferase NatA |
hippocampus |
- |
756675 |
2.3.1.297 | very-long-chain ceramide synthase |
hippocampus |
- |
736217 |
2.3.1.42 | glycerone-phosphate O-acyltransferase |
hippocampus |
- |
658362 |
2.3.1.50 | serine C-palmitoyltransferase |
hippocampus |
increased expression of SPT in reactive astrocytes of the hippocampus after kainate injections is shown |
675555 |
2.3.1.50 | serine C-palmitoyltransferase |
hippocampus |
increased SPT enzyme activity in reactive astrocytes of the hippocampus at 2 weeks post-kainate injection |
675555 |
2.3.1.6 | choline O-acetyltransferase |
hippocampus |
- |
487324, 705281, 705905, 705919, 736678 |
2.3.1.6 | choline O-acetyltransferase |
hippocampus |
64% of activity membrane associated |
660007 |
2.3.1.6 | choline O-acetyltransferase |
hippocampus |
ChAt activity in untreated and in pilocarpine-treated hippocampi, overview |
703135 |
2.3.1.6 | choline O-acetyltransferase |
hippocampus |
ChAT activity is increased at 10 and 12 months of age in the hippocampus of Ts65Dn mice compared to normogenic animals |
689183 |
2.3.1.6 | choline O-acetyltransferase |
hippocampus |
cholinergic neuron-specific ChAT in the CA1 region of hippocampus |
702958 |
2.3.1.6 | choline O-acetyltransferase |
hippocampus |
exposure to enriched environment improves spatial learning performances and enhances cell density but not choline acetyltransferase activity in the hippocampus of ventral subicular-lesioned rats |
684814 |
2.3.1.6 | choline O-acetyltransferase |
hippocampus |
in both young adult and middle-aged animals, oestradiol treatment initiates immediately after ovariectomy significantly increased ChAT levels in the hippocampus but not in the prefrontal cortex compared to cholesterol control treatment. When oestradiol treatment is initiated 5 months after ovariectomy, it fails to significantly increase ChAT levels in the hippocampus, but does so in the prefrontal cortex |
688529 |
2.3.1.6 | choline O-acetyltransferase |
hippocampus |
increased ChAT activity in some brain regions, notably the hippocampus, of patients diagnosed with mild cognitive impairment |
689183 |
2.3.1.61 | dihydrolipoyllysine-residue succinyltransferase |
hippocampus |
- |
487343 |
2.3.1.B41 | protein-long-chain fatty-acyl-lysine deacylase (NAD+) |
hippocampus |
- |
756392 |
2.3.2.2 | gamma-glutamyltransferase |
hippocampus |
decrease in the hippocampal GGT decreases 2 h after the intravenous injection of 0.005 mg IL-1beta, increaes after 24 h and returns to control levels after 96 h. No significant changes in the hippocampal GGT activity are observed at 2 h and 24 h following the intracerebroventricular infusion of 50 ng IL-1beta |
676350 |